19.02.2013 Views

4th EucheMs chemistry congress

4th EucheMs chemistry congress

4th EucheMs chemistry congress

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

thursday, 30-Aug 2012<br />

s779<br />

chem. Listy 106, s587–s1425 (2012)<br />

organic Chemistry, Polymers – i<br />

Natural products, Drugs – iii<br />

o - 4 8 7<br />

CASe StudieS of ASyMMetriC hydroGenAtion<br />

of ChALLenGinG PhArMACeutiCALLy<br />

reLevAnt SuBStrAteS<br />

v. JurCiK 1<br />

1 Johnson Matthey Catalysts, Chiral Catalysts and<br />

Technologies, Cambridge, United Kingdom<br />

Two recent case studies of asymmetric hydrogenation of<br />

unusual and challenging pharmaceutically relevant substrates will<br />

be presented. Emphasis on challenges of industrially applicable<br />

catalytic transformations will be given.<br />

First case study will show efficient asymmetric<br />

hydrogenation of (1-chlorovinyl) boronates. [1]<br />

Broad range of substituted (1-chlorovinyl) boronates, with<br />

different steric and electronic properties, can be successfully<br />

hydrogenated in the presence of P^N-iridium catalysts without<br />

significant cleavage of the C-Cl bond.<br />

It will be shown how rational modification of the<br />

structural properties of the P^N ligands can result in new<br />

N-acyl-imidazoline ferrocenyl-based iridium catalysts with broad<br />

substrate acceptance. With these catalysts, excellent conversions,<br />

high chemoselectivities (with dechlorinated byproducts in the<br />

range of 3–19%), and enantioselectivities of up to 94%ee can be<br />

obtained. The utility of the hydrogenation method presented will<br />

be demonstrated on preparation of a key precursor for the<br />

construction of the anticancer drug bortezomib.<br />

Second case study will deal with development of<br />

asymmetric hydrogenation of a pyridyl benzo thiophene alkene. [2]<br />

Studied transformation represents a key step in enantioselective<br />

synthesis of NBI-75043, a selective and potent H1 antagonist for<br />

the treatment of insomnia.<br />

Reduction can be successfully accomplished using<br />

[BoPhoz Rh] catalysts. By tailoring the steric properties of the<br />

BoPhoz ligand, the ee of the product can be increased from just<br />

12% to 90%. This research further expands the substrate scope<br />

of the conventional class of functionalized alkenes amenable<br />

to catalytic asymmetric hydrogenation.<br />

references:<br />

1. Angew. Chem. Int. Ed. 2012, 51, 1014–1018<br />

2. Tet. Lett. 2012, 53, 1025–1028<br />

Keywords: Asymmetric catalysis; Hydrogenation;<br />

4 th <strong>EucheMs</strong> <strong>chemistry</strong> <strong>congress</strong><br />

AUGUst 26–30, 2012, PrAGUE, cZEcH rEPUbLIc

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!